Ardelyx Appoints Sue Hohenleitner as Chief Financial Officer, Succeeding Justin Renz
Reuters
Oct 13, 2025
<a href="https://laohu8.com/S/ARDX">Ardelyx</a> Appoints Sue Hohenleitner as Chief Financial Officer, Succeeding Justin Renz
Ardelyx Inc. has announced the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner brings over 30 years of experience in corporate finance and previously served as Vice President and CFO of Johnson & Johnson Innovative Medicine North America. She will succeed Justin Renz, who will remain in his role through the completion of Ardelyx's third quarter financial reporting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544245-en) on October 13, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.